Clene Stock Price, News & Analysis (NASDAQ:CLNN) $0.41 +0.01 (+1.28%) (As of 12:25 PM ET) Add Compare Share Share Today's Range$0.40▼$0.4250-Day Range$0.38▼$0.5452-Week Range$0.36▼$1.99Volume211,009 shsAverage Volume579,810 shsMarket Capitalization$52.02 millionP/E RatioN/ADividend YieldN/APrice Target$7.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Clene MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,822.6% Upside$7.80 Price TargetShort InterestHealthy0.45% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$102,501 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.28) to ($0.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.15 out of 5 starsMedical Sector381st out of 958 stocksPharmaceutical Preparations Industry131st out of 393 stocks 3.5 Analyst's Opinion Consensus RatingClene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.80, Clene has a forecasted upside of 1,822.6% from its current price of $0.41.Amount of Analyst CoverageClene has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.45% of the outstanding shares of Clene have been sold short.Short Interest Ratio / Days to CoverClene has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clene has recently decreased by 15.36%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldClene does not currently pay a dividend.Dividend GrowthClene does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLNN. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 16 people have searched for CLNN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows11 people have added Clene to their MarketBeat watchlist in the last 30 days. This is an increase of 175% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Clene insiders have bought more of their company's stock than they have sold. Specifically, they have bought $102,501.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders26.60% of the stock of Clene is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.87% of the stock of Clene is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Clene are expected to decrease in the coming year, from ($0.28) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Clene is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Clene is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClene has a P/B Ratio of 10.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Clene Stock (NASDAQ:CLNN)Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Read More CLNN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLNN Stock News HeadlinesNovember 23, 2023 | finance.yahoo.comClene Capitalizing on Promising Chemical and Therapeutic Properties of NanocrystalsNovember 15, 2023 | finance.yahoo.comInsider Spends US$103k Buying More Shares In CleneDecember 7, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 9, 2023 | finance.yahoo.comClene Announces Q3 2023 Financial Results, Operating HighlightsNovember 9, 2023 | markets.businessinsider.comBenchmark Co. Keeps Their Buy Rating on Clene (CLNN)November 7, 2023 | msn.comClene GAAP EPS of -$0.02, revenue of $0.11MNovember 7, 2023 | finance.yahoo.comClene Reports Third Quarter 2023 Financial Results and Operating HighlightsNovember 7, 2023 | finance.yahoo.comClene Inc (CLNN) Reports Q3 2023 Financial Results: Significant Survival Benefits and $45.December 7, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 7, 2023 | finance.yahoo.comClene Inc (CLNN) Reports Q3 2023 Financial Results: Significant Survival Benefits and $45. ...October 31, 2023 | finance.yahoo.comClene Reports Improved Survival Status in ALS Patients Treated with CNM-Au8(R) on Follow-Up AnalysisOctober 26, 2023 | finance.yahoo.comClene Inc. (CLNN) Interactive Stock Chart - Yahoo FinanceOctober 26, 2023 | finance.yahoo.comClene Announces Four-Year Grant to Support Expanded Access Protocol for CNM-Au8 From NINDSOctober 19, 2023 | finance.yahoo.comClene 'Innovates' Investigational Drug With Patented NanotechnologyOctober 17, 2023 | finance.yahoo.comClene Applies Patented Nanotechnology to Development of CNM-Au8(R), Its Investigational Drug for ALSOctober 11, 2023 | finance.yahoo.comClene CEO Featured in Latest Episode of The Bell2Bell PodcastOctober 7, 2023 | markets.businessinsider.comPromising Potential of Clene’s CNM-Au8 in Neurological Treatment Boosts Stock Buy RatingOctober 6, 2023 | msn.comClene (CLNN) Price Target Increased by 6.29% to 6.32October 5, 2023 | markets.businessinsider.comPromising Future for Clene’s Stock: NIH Grant and Encouraging Clinical Results Boost ConfidenceOctober 5, 2023 | finance.yahoo.comNational Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALSSeptember 29, 2023 | finance.yahoo.comClene Investigational Drug Focus of Study Published in Peer-Reviewed JournalSeptember 29, 2023 | finance.yahoo.comClene Inc. Is 'One to Watch'September 29, 2023 | theglobeandmail.comClene (NASDAQ: CLNN) Investigational Drug Focus of Study Published in Peer-Reviewed JournalSeptember 28, 2023 | stockhouse.comClene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of ActionSeptember 28, 2023 | finance.yahoo.comClene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of ActionSeptember 27, 2023 | finance.yahoo.comClene Releases Significant Long-Term Survival Improvement Data from ALS TrialSeptember 26, 2023 | markets.businessinsider.comPromising Efficacy and Safety Data for Clene’s CNM-Au8 Spurs Buy Rating Recommendation: Anticipating Accelerated Approval and NDA Filing by 2024See More Headlines Receive CLNN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clene and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/07/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/11/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CLNN CUSIPN/A CIK1822791 Webclene.com Phone801-676-9695FaxN/AEmployees75Year FoundedN/APrice Target and Rating Average Stock Price Target$7.80 High Stock Price Target$13.00 Low Stock Price Target$4.00 Potential Upside/Downside+1,850.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,920,000.00 Net Margins-5,624.65% Pretax Margin-5,624.65% Return on Equity-322.31% Return on Assets-67.52% Debt Debt-to-Equity Ratio0.78 Current Ratio3.04 Quick Ratio3.04 Sales & Book Value Annual Sales$718,000.00 Price / Sales71.54 Cash FlowN/A Price / Cash FlowN/A Book Value$0.04 per share Price / Book10.00Miscellaneous Outstanding Shares128,416,000Free Float94,257,000Market Cap$51.37 million OptionableNot Optionable Beta0.53 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Robert Etherington MBA (Age 56)CEO, President & Director Comp: $590.98kMr. Morgan R. Brown CPA (Age 55)M.B.A., Chief Financial Officer Comp: $374.05kMr. Mark G. Mortenson ESQ. (Age 65)Chief Science Officer Comp: $482.98kMr. Jerry Miraglia J.D.General Counsel & Corporate SecretaryMr. Michael T. HotchkinChief Development OfficerMs. Mary Anne McneilHead of Human ResourcesDr. Benjamin M. Greenberg M.D.M.H.S., Head of MedicalMore ExecutivesKey CompetitorsYS BiopharmaNASDAQ:YSRockwell MedicalNASDAQ:RMTICervoMedNASDAQ:CRVOAcurx PharmaceuticalsNASDAQ:ACXPLongeveronNASDAQ:LGVNView All CompetitorsInsiders & InstitutionsWorth Venture Partners LLCSold 78,309 shares on 11/15/2023Ownership: 1.094%Kepos Capital LPSold 38,678 shares on 11/15/2023Ownership: 0.102%AIGH Capital Management LLCSold 135,622 shares on 11/13/2023Ownership: 4.518%Silverarc Capital Management LLCBought 250,000 shares on 11/13/2023Ownership: 0.389%David J MatlinBought 250,002 shares on 11/10/2023Total: $102,500.82 ($0.41/share)View All Insider TransactionsView All Institutional Transactions CLNN Stock Analysis - Frequently Asked Questions Should I buy or sell Clene stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clene in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CLNN shares. View CLNN analyst ratings or view top-rated stocks. What is Clene's stock price target for 2024? 6 brokers have issued 12 month price objectives for Clene's stock. Their CLNN share price targets range from $4.00 to $13.00. On average, they expect the company's share price to reach $7.80 in the next twelve months. This suggests a possible upside of 1,822.6% from the stock's current price. View analysts price targets for CLNN or view top-rated stocks among Wall Street analysts. How have CLNN shares performed in 2023? Clene's stock was trading at $1.00 on January 1st, 2023. Since then, CLNN shares have decreased by 59.4% and is now trading at $0.4057. View the best growth stocks for 2023 here. When is Clene's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 11th 2024. View our CLNN earnings forecast. How were Clene's earnings last quarter? Clene Inc. (NASDAQ:CLNN) released its earnings results on Tuesday, November, 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.08. The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.14 million. Clene had a negative trailing twelve-month return on equity of 322.31% and a negative net margin of 5,624.65%. Who are Clene's major shareholders? Clene's stock is owned by a variety of retail and institutional investors. Top institutional investors include AIGH Capital Management LLC (4.52%), Vivo Capital LLC (2.06%), Worth Venture Partners LLC (1.09%), Silverarc Capital Management LLC (0.39%), AE Wealth Management LLC (0.13%) and Kepos Capital LP (0.10%). Insiders that own company stock include Alison Mosca, David J Matlin, David J Matlin, General Resonance Llc, John Henry Stevens, Jonathon Gay, Robert Dee Etherington and Robert Glanzman. View institutional ownership trends. How do I buy shares of Clene? Shares of CLNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CLNN) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.